StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

Equities researchers at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, March 18th.

Can-Fite BioPharma Stock Performance

Shares of NYSE CANF opened at $1.62 on Friday. The firm has a 50 day moving average price of $1.59 and a 200 day moving average price of $1.86. The stock has a market cap of $5.73 million, a P/E ratio of -0.91 and a beta of 1.12. Can-Fite BioPharma has a 52-week low of $1.29 and a 52-week high of $4.69.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers lifted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.